# Useful features

**Referances**

[1] Frost L. S. (1992). Bacterial conjugation: everybody's doin' it. *Canadian journal of microbiology*, *38*(11), 1091–1096. https://doi.org/10.1139/m92-179

[2] Fischbach, W., & Malfertheiner, P. (2018). Helicobacter Pylori Infection. Deutsches Arzteblatt international, 115(25), 429–436. https://doi.org/10.3238/arztebl.2018.0429

[3] Ren, S., Cai, P., Liu, Y., Wang, T., Zhang, Y., Li, Q., Gu, Y., Wei, L., Yan, C., & Jin, G. (2022). Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis. *Journal of gastroenterology and hepatology*, *37*(3), 464–470. https://doi.org/10.1111/jgh.15751

[4] Ko, S. W., Kim, Y. J., Chung, W. C., & Lee, S. J. (2019). Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. *Helicobacter*, *24*(2), e12565. https://doi.org/10.1111/hel.12565

[5] McNicholl, A. G., Bordin, D. S., Lucendo, A., Fadeenko, G., Fernandez, M. C., Voynovan, I., Zakharova, N. V., Sarsenbaeva, A. S., Bujanda, L., Perez-Aisa, Á., Vologzhanina, L., Zaytsev, O., Ilchishina, T., Coba, C., Lasala, J. P., Alekseenko, S., Modolell, I., Molina-Infante, J., Ruiz-Zorrilla Lopez, R., Alonso-Galan, H., … Gisbert, J. P. (2020). Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, *18*(1), 89–98. https://doi.org/10.1016/j.cgh.2019.03.048

[6] Yang, X., Wang, J. X., Han, S. X., & Gao, C. P. (2019). High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. *Medicine*, *98*(7), e14396. https://doi.org/10.1097/MD.0000000000014396

[7] Nishida, T., Tsujii, Y., Okamoto, A., Tomita, R., Higaki, Y., Osugi, N., Sugimoto, A., Takahashi, K., Mukai, K., Nakamatsu, D., Matsubara, T., Hayashi, S., Yamamoto, M., Nakajima, S., Fukui, K., & Inada, M. (2020). A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study. *Digestion*, *101*(5), 608–614. https://doi.org/10.1159/000501608

[8]Zhou, B. G., Chen, L. X., Li, B., Wan, L. Y., & Ai, Y. W. (2019). Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. *Helicobacter*, *24*(5), e12651. https://doi.org/10.1111/hel.12651

[9] Fang, H. R., Zhang, G. Q., Cheng, J. Y., & Li, Z. Y. (2019). Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. *European journal of pediatrics*, *178*(1), 7–16. https://doi.org/10.1007/s00431-018-3282-z

[10] Wu, L., Wang, Z., Sun, G., Peng, L., Lu, Z., Yan, B., Huang, K., & Yang, Y. (2019). Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer. *Scientific reports*, *9*(1), 12874. https://doi.org/10.1038/s41598-019-49415-3

[11] Liang, Y., Yan, J., Chen, Z., Gu, Q., & Li, P. (2022). Antibacterial Effects of Bacteriocin PLNC8 against *Helicobacter pylori* and Its Potential Mechanism of Action. *Foods (Basel, Switzerland)*, *11*(9), 1235. https://doi.org/10.3390/foods11091235
